Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2024

Genmab — Februar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #108

    Håber at de får en stor spiller, hvis de har endnu et guldkorn i pipelinen. Synes stadig ikke de har erfaring nok til at løfte et kæmpe klinisk projekt alene eller sammen med BioNTech.

    1 Reply Last reply
    0
    • JørgenVarnæsJ Offline
      JørgenVarnæsJ Offline
      JørgenVarnæs
      wrote on sidst redigeret af
      #109

      tilsammen har de 2 en krigskasse, der kan løfte lidt af hvert. Ikke siden zalutumumab har GEN lagt "dollars to donuts" - og jeg har savnet vilje til udvikling fra GENs side

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #110

        Vi er nok alle irriteret over kursen ikke er over 3000. Aktiekursen har sit eget liv, som JW siger. Vi kan ikke pege på en præcis årsag til at kursen roder rundt hernede. I min optik er kursen for lav. Men hvornår det bliver bedre vil jeg ikke gætte på.

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #111

          Vilje til udvikling ? Kig på R&D omkostningerne.

          1 Reply Last reply
          0
          • JørgenVarnæsJ Offline
            JørgenVarnæsJ Offline
            JørgenVarnæs
            wrote on sidst redigeret af
            #112

            Masser af R, begrænset D og tungetunge administrationsomkostninger

            1 Reply Last reply
            0
            • JørgenVarnæsJ Offline
              JørgenVarnæsJ Offline
              JørgenVarnæs
              wrote on sidst redigeret af
              #113

              var det ikke Novod, der kaldte set-uppet for "døde penge"

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #114

                the 50/50 split Genmab wants is a significant hurdle for partnerships with big pharma i believe. and very possibly one of the reasons some of the larger bi-specific deals we have seen over the last few months were not with genmab technology. But i can't blame them for pursuing 50/50, after what happened with JNJ, i would also not want to be in a position like that again...

                1 Reply Last reply
                0
                • JørgenVarnæsJ Offline
                  JørgenVarnæsJ Offline
                  JørgenVarnæs
                  wrote on sidst redigeret af
                  #115

                  But it's really not that hard - once you have run the safety/dose escalation part of the clinical development, you are in a very different place negotiation-wise. GEN has done very little of this. In fact, it seems they need to partner with other companies to have the necessary tech to even get programs into the clinic

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #116

                    If Genmab want and ADC for instance they need to partner up with a ADC company like everyone else

                    1 Reply Last reply
                    0
                    • JørgenVarnæsJ Offline
                      JørgenVarnæsJ Offline
                      JørgenVarnæs
                      wrote on sidst redigeret af
                      #117

                      Apart from hexa - when was the last time we saw results from the clinic on new programs?

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #118

                        Thats a good thing I think - different targets needs different tech

                        1 Reply Last reply
                        0
                        • JørgenVarnæsJ Offline
                          JørgenVarnæsJ Offline
                          JørgenVarnæs
                          wrote on sidst redigeret af
                          #119

                          how is KYSO the same as the need to enter 50/50 partnerships to get something off the ground?

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #120

                            on ADC; to be honest, i had expected something from their collaboration with Abbvie there, Jan was very enthusiastic at the time on Abbvie's ADC technology

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #121

                              but we haven't seen anything with Abbvie really besides epco

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #122

                                JV, epco was 50/50 after initial development

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #123

                                  they stopped a few programs, eg HexaBody-DR5/DR5
                                  , DuoHexabody-CD37, DuoBody-CD3x5T4

                                  ,

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #124

                                    that is not something you hope for in advance offcourse, ideally these would have gone further allready

                                    1 Reply Last reply
                                    0
                                    • JørgenVarnæsJ Offline
                                      JørgenVarnæsJ Offline
                                      JørgenVarnæs
                                      wrote on sidst redigeret af
                                      #125

                                      EL, indeed. But where are all the other programs showing clinical promise?

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #126

                                        So far we've seen nothing from the Biontech collab but vailed hints about synergistic effect. I can't point to a single thing in the pipeline with the potential to break through

                                        1 Reply Last reply
                                        0
                                        • R Offline
                                          R Offline
                                          Raun
                                          wrote on sidst redigeret af
                                          #127

                                          Tak for din vurdering @Solsen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper